UBS raised the firm’s price target on Amgen to $337 from $307 and keeps a Neutral rating on the shares as part of a Q2 earnings preview for the U.S. pharmaceuticals group. The firm is in line with consensus estimates for Q2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN: